BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S, Nagy A, Hussein MS, Yosry A, Esmat G. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. J Med Virol. 2017;89:2181-2187. [PMID: 28688190 DOI: 10.1002/jmv.24897] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Jiang Y, Zhou L. Association between chronic hepatitis C infection and metabolic syndrome: A meta-analysis. Nutrition Clinique et Métabolisme 2022. [DOI: 10.1016/j.nupar.2022.03.002] [Reference Citation Analysis]
2 Abdel Fattah NK, Shaheen SM, Ahmed OA, Elsaeed K, Sabri NA. Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals. F1000Res 2022;11:649. [DOI: 10.12688/f1000research.109397.1] [Reference Citation Analysis]
3 Hagag RY, Selim AF, Darrag OM, Zied H, Aboelnasr MS. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy? Diabetes Metab Syndr Obes 2022;15:1261-8. [PMID: 35502409 DOI: 10.2147/DMSO.S354023] [Reference Citation Analysis]
4 Ciardullo S, Mantovani A, Ciaccio A, Carbone M, Invernizzi P, Perseghin G. Hepatitis C virus infection and diabetes: A complex bidirectional relationship. Diabetes Research and Clinical Practice 2022;187:109870. [DOI: 10.1016/j.diabres.2022.109870] [Reference Citation Analysis]
5 Abdo M, Rabiee A, Abdellatif Z, Abdel Alem S, Moustafa A. Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. Eur J Gastroenterol Hepatol 2021;33:1588-94. [PMID: 32804853 DOI: 10.1097/MEG.0000000000001903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Hegazy WAH, Rajab AAH, Abu Lila AS, Abbas HA. Anti-diabetics and antimicrobials: Harmony of mutual interplay. World J Diabetes 2021; 12(11): 1832-1855 [PMID: 34888011 DOI: 10.4239/wjd.v12.i11.1832] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
7 Mahmoud B, Moneim AA, Mabrouk D. The impact of HCV eradication on hyperglycemia, insulin resistance, cytokine production, and insulin receptor substrate-1 and 2 expression in patients with HCV infection. Clin Exp Med 2021. [PMID: 34757525 DOI: 10.1007/s10238-021-00773-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C, Ungprasert P. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res 2020;152:562-7. [PMID: 34145095 DOI: 10.4103/ijmr.IJMR_1088_18] [Reference Citation Analysis]
10 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 El Badry MM, Ali DA, Eltaweel NH, Abdel-wahed MA. Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00061-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Zhang JY, Cooper C, Doyle M. Association between hepatitis C antiviral treatment and diabetes mellitus: A case series. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2020;5:104-110. [DOI: 10.3138/jammi-2019-0007] [Reference Citation Analysis]
14 Nevola R, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020;4:713-721. [PMID: 32782961 DOI: 10.1002/jgh3.12324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
15 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
16 Hussein HA, Allam AS, Moaty ASA. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir. Curr Diabetes Rev 2020;16:165-70. [PMID: 31146663 DOI: 10.2174/1573399815666190531091128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Russo FP, Zanetto A, Gambato M, Bortoluzzi I, Al Zoairy R, Franceschet E, De Marchi F, Marzi L, Lynch EN, Floreani A, Farinati F, Schaefer B, Burra P, Zoller H, Mega A. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J Viral Hepat 2020;27:188-94. [PMID: 31596996 DOI: 10.1111/jvh.13215] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
18 Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 348] [Cited by in F6Publishing: 357] [Article Influence: 116.0] [Reference Citation Analysis]
19 Mada PK, Malus ME, Parvathaneni A, Chen B, Castano G, Adley S, Moore M, Hieda M, Alam MJ, Feldman M, King JW. Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus. Int J Hepatol 2020;2020:6438753. [PMID: 32395351 DOI: 10.1155/2020/6438753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
21 Gilad A, Fricker ZP, Hsieh A, Thomas DD, Zahorian T, Nunes DP. Sustained Improvement in Type 2 Diabetes Mellitus is Common After Treatment of Hepatitis C Virus With Direct-acting Antiviral Therapy. J Clin Gastroenterol 2019;53:616-20. [PMID: 30614943 DOI: 10.1097/MCG.0000000000001168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
22 Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, Kattakuzhy S, Rosenthal E, Kottilil S, Masur H. No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV. J Infect Dis. 2017;217:47-50. [PMID: 29161418 DOI: 10.1093/infdis/jix517] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
23 Carnovale C, Pozzi M, Dassano A, D'Addio F, Gentili M, Magni C, Clementi E, Radice S, Fiorina P. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetol 2019;56:341-54. [PMID: 30478781 DOI: 10.1007/s00592-018-1257-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
24 Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents 2019;53:559-63. [PMID: 30550818 DOI: 10.1016/j.ijantimicag.2018.11.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
25 Fazekas-Lavu M, Tonks KTT, Samaras K. Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience. Front Endocrinol (Lausanne) 2018;9:634. [PMID: 30429826 DOI: 10.3389/fendo.2018.00634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Can J Gastroenterol Hepatol 2018;2018:6095097. [PMID: 30402450 DOI: 10.1155/2018/6095097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
27 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
28 Adinolfi LE, Rinaldi L, Marrone A, Giordano M. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. Expert Rev Anti Infect Ther. 2018;16:595-597. [PMID: 30047799 DOI: 10.1080/14787210.2018.1505500] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]